Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMedOpen access

Wound Healing: Harnessing Extracellular Vesicles Derived from Adipose-Derived Stem Cells.

Liu Q., Zhang C., Liang Y., Pan X.

Narrative Review on Diabetic Foot, Chronic Wound, Scar, published in Int J Nanomedicine (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Nanomedicine (2025)
Country
New Zealand
Reported sample size
—
Source database
PubMed
PMID
41200265
PMCID
PMC12587863
DOI
10.2147/IJN.S546521

Abstract (original English)

Chronic wounds present a significant clinical challenge, placing a heavy burden on patients and highlighting the need for more effective treatments. Among emerging strategies, adipose-derived stem cells (ADSCs) and their extracellular vesicles (ADSC-EVs) show great promise due to their potent wound-healing capabilities. Clinical evidence indicates that ADSC transplantation effectively promotes healing across diverse chronic wound types, improving healing quality while reducing pathological scarring. As key paracrine mediators of ADSCs, ADSC-EVs have garnered considerable interest for their advantages in therapeutic development and reparative functions. ADSC-EVs precisely modulate critical cells within the wound microenvironment, including keratinocytes, macrophages, endothelial cells, and fibroblasts. This modulation promotes re-epithelialization, resolves inflammation, stimulates angiogenesis, and modulates extracellular matrix remodeling. These regulatory effects are attributed to the rich cargo of bioactive molecules carried by ADSC-EVs, including proteins and non-coding RNAs. Notably, preconditioning strategies and functional delivery materials can further enhance the modulatory effects of ADSC-EVs by enriching them with specific therapeutic molecules and enabling controlled release. Furthermore, ADSC-EVs serve as efficient drug delivery vehicles for exogenous therapeutics,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansExtracellular VesiclesWound HealingAdipose TissueAnimalsStem CellsDrug Delivery Systems

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research